2-iodo-5-isopropoxy-4-methoxybenzaldehyde | 200941-15-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-iodo-5-isopropoxy-4-methoxybenzaldehyde
• 英文别名: 2-iodo-4-methoxy-5-propan-2-yloxybenzaldehyde
• CAS: 200941-15-7
• 化学式: C₁₁H₁₃IO₃
• 分子量: 320.127
• InChiKey: ABFXAWUBURKXCT-UHFFFAOYSA-N

物化性质

• 沸点：
  374.0±42.0 °C(Predicted)
• 密度：
  1.564±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-iodo-5-isopropoxy-4-methoxybenzaldehyde 在 bis-triphenylphosphine-palladium(II) chloride copper(l) iodide 、 碳酸氢钠 、 potassium carbonate 、 三乙胺 、 间氯过氧苯甲酸 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 27.5h， 生成 1-Ethynyl-2,4-diisopropoxy-5-methoxy-benzene
  参考文献：
  名称：

  Syntheses of Lamellarins I and K by [3 + 2] Cycloaddition of a Nitrone to an Alkyne

  摘要：

  层层素 I 和 K 是通过一种新方法获得的，该方法基于腈氧化物与炔烃的 1,3-双极环加成反应。关键的环加成反应产生了异噁唑啉，随后重排形成中心吡咯环。

  DOI：

  10.1055/s-2001-15143
• 作为产物：
  描述：

  3-异丙基-4-甲氧基苯甲醛 在 碘 、 silver trifluoroacetate 作用下， 以 氯仿 为溶剂， 反应 7.0h， 以93%的产率得到2-iodo-5-isopropoxy-4-methoxybenzaldehyde
  参考文献：
  名称：

  Convergent total synthesis of lamellarin K†

  摘要：

  由二氢异喹啉盐24衍生的偶氮亚甲基季铵盐发生一种分子内[3 + 2]环加成反应，生成吡咯25，该吡咯经过去异丙基化反应得到海洋生物碱拉梅拉林K 4。

  DOI：

  10.1039/a705874h

文献信息

• Synthesis, X-Ray Crystal Structure and Tubulin- Binding Properties of a Benzofuran Analogue of the Potent Cytotoxic Agent Combretastatin A4
  作者：Martin G. Banwell、Bernard L. Flynn、Ernest Hamel、Anthony C. Willis

  DOI：10.1071/ch99022

  日期：——

  The benzofuran (4), a ring-fused analogue of the potent antimitotic agent combretastatin A4 (1), has been prepared by a convergent route involving 5-endo-dig iodocyclization of o-hydroxytolan (5) as the key step. Compound (4), which has been characterized crystallographically as well as spectroscopically, is inactive as a tubulin-binding agent.

  苯并呋喃（4）是强效抗胆碱能药物 苯并呋喃（4）是一种环状融合的类似物，其制备方法包括 5-endo-dig iodocyclization of 5-endo-dig iodocyclization of o-hydroxytolan (5) 作为关键步骤。化合物 (4) 在晶体学和光谱学上均有表征，但其作为小管蛋白结合剂并无活性。 作为一种小管蛋白结合剂不具有活性。
• Preparation of fused polycyclic alkaloids by ring closure of azomethine ylides, novel compounds thereof and their use as chemotherapeutic agents
  申请人：——

  公开号：US20030208076A1

  公开（公告）日：2003-11-06

  A method for the preparation of a compound of general Formula: 1 or pharmaceutically acceptable derivatives and salts, racemates, isomers and/or tautomers thereof comprising cyclizing an azomethine ylide of general Formula: 2 wherein A is a cyclic or non-cyclic group; Z is a carbon or a heteroatom; n is selected from 0, 1, 2 or 3; W, X and Y may be the same or different and each are selected from hydrogen; optionally substituted alkyl, alkenyl, alkynyl, amino, alkoxy, alkenoxy, alkynoxy, aryl, alkylthio, heterocyclyl; carboxy, carboxy ester, carboxamido, acyl, acyloxy, mercapto, halogen, nitro, sulfate, phosphate, cyano and optionally protected hydroxy; or W and X, together with the nitrogen and carbon atoms to which they are attached, form a saturated or unsaturated nitrogen containing heterocyclic group which may be optionally substituted or optionally fused to a saturated or unsaturated carbocyclic group, aryl group or heterocyclic group is provided.

  一种制备通式1化合物或其药学上可接受的衍生物、盐、外消旋体、异构体和/或互变异构体的方法，包括环化通式2的偶氮甲基亚胺，其中A是环状或非环状基团；Z是碳或杂原子；n从0、1、2或3中选择；W、X和Y可以相同也可以不同，每个都是氢；可选择取代的烷基、烯基、炔基、氨基、烷氧基、烯氧基、炔氧基、芳基、烷硫基、杂环基；羧基、羧酯、羧酰胺、酰基、酰氧基、巯基、卤素、硝基、硫酸酯、磷酸酯、氰基和可选择保护的羟基；或者W和X与它们所连接的氮和碳原子一起形成饱和或不饱和的含氮杂环基团，该基团可以选择取代或可选择融合到饱和或不饱和的碳环基团、芳基或杂环基团中。
• NON-STEROIDAL COMPOUNDS
  申请人：Stewart Alastair

  公开号：US20120046255A1

  公开（公告）日：2012-02-23

  The present invention relates to non-steroidal compounds useful in the treatment of inflammatory conditions and pharmaceutical compositions comprising them. A representative example of these compounds is

  本发明涉及非甾体化合物，可用于治疗炎症状况，以及包含它们的制药组合物。这些化合物的代表性例子是：
• Non-steroidal compounds
  申请人：Stewart Alastair

  公开号：US08536157B2

  公开（公告）日：2013-09-17

  The present invention relates to non-steroidal compounds useful in the treatment of inflammatory conditions and pharmaceutical compositions comprising them. A representative example of these compounds is

  本发明涉及非甾体化合物，其在治疗炎症性疾病方面有用，并且包括它们的制药组合物。这些化合物的代表性例子是
• Total synthesis and evaluation of lamellarin α 20-Sulfate analogues
  作者：C Ridley

  DOI：10.1016/s0968-0896(02)00237-7

  日期：2002.10

  In order to explore the influence of sulfate groups on the bioactivity profiles of marine alkaloids of the lamellarin class, three such alkaloids, lamellarin alpha, lamellarin alpha 13,20-disulfate and lamellarin H, were synthesized and their activities against HIV-1 integrase and cancer cell lines were compared with those of lamellarin alpha 20-sulfate, which is a selective inhibitor of HIV-1 integrase. Lamellarin alpha does not inhibit HIV-1 integrase but shows moderate cytotoxicity with good cell line selectivity. Lamellarin alpha 13,20-disulfate is a moderate inhibitor of both HIV-1 integrase and cancer cell lines. Lamellarin H is a more potent inhibitor of HIV-1 integrase but lacked the specificity required to be medicinally useful. (C) 2002 Elsevier Science Ltd. All rights reserved.